Search

Search Results

• SYSTEMIC MASTOCYTOSIS: MOLECULAR LANDSCAPE AND IMPLICATIONS FOR TREATMENT

  Cecilia Monaldi, Sara De Santis, Manuela Mancini, Samantha Bruno, Michele Cavo, Simona Soverini

  e2021046

  2021-06-28

  https://doi.org/10.4084/MJHID.2021.046

  1351

  PDF: 632

  HTML: 237

• THE JAK2V617F POINT MUTATION INCREASES THE OSTEOCLAST FORMING ABILITY OF MONOCYTES IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS AND MAKES THEIR OSTEOCLASTS MORE SUSCEPTIBLE TO JAK2 INHIBITION

  Emmanouil Spanoudakis, Menelaos Papoutselis, Ioanna Bazntiara, Eleftheria Lamprianidou, Xrisa Kordella, Constantinos Tilkeridis, Constantinos Tsatalas, Ioannis Kotsianidis

  e2018058

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.058

  1314

  PDF: 807

  HTML: 171

• IS ALLOGENEIC TRANPLANTATION AN OPTION IN PATIENTS AFFECTED BY CONCURRENT MYELOFIBROSIS AND CHRONIC MYELOID LEUKEMIA (CML)?

  Federica Sorà, Patrizia Chiusolo, Francesco autore, Sabrina Giammarco, luca laurenti, elisabetta metafuni, idanna innocenti, eugenio galli, andrea bacigalupo, simona sica

  e2021062

  2021-10-29

  https://doi.org/10.4084/MJHID.2021.062

  1190

  PDF: 447

  HTML: 145

• Can Polycythemia Vera evolve from Acute Myeloid Leukemia? A Case Report Showing a Simultaneous Minor JAK2 V617F Mutated Clone, De novo polycythemia vera following AML remission

  Beatrice Borsellino, Arianna Savi, Maria Rosaria Pascale, Elisa Meddi, Antonio Cristiano, TIZIANA OTTONE, Maria Cristina Rapanotti, Mariadomenica Divona, SERENA TRAVAGLINI, Enrico Attardi, Elisa Buzzatti, Francesco Buccisano, Maria Teresa Voso

  e2022058

  2022-06-29

  https://doi.org/10.4084/MJHID.2022.058

  1609

  PDF: 732

  HTML: 228

• Lung Clear “Sugar” Cell Tumor and Jak V617f Positive Essential Thrombocythemia: A simple Co?nc?dence?

  Volkan Yazak, Gokhan Sargin, Irfan Yavasoglu, Gurhan Kadikoylu, Canten Tataroglu, Gokay Bozkurt, Zahit Bolaman

  e2013021

  2013-04-10

  https://doi.org/10.4084/mjhid.2013.021

  1238

  PDF: 693

  HTML: 2605

• UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)

  José Luis Piñana, Estela Giménez, Lourdes Vázquez, María Ángeles Marcos, Manuel Guerreiro, Rafael Duarte, Ariadna Pérez, Carlos de Miguel, Ildefonso Espigado, Marta González-Vicent, María Suarez-Lledó, Irene García-Cadenas, Rodrigo Martino, Angel Cedillo, Monserrat Rovira, Rafael de la Cámara, David Navarro, Carlos Solano

  e2024065

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.065

  3813

  Suppl. Files: 1075

  PDF: 1039

  Html: 157

• THE Co-Occurrence of Jak2/Calr-Positive Myeloproliferative Disorder and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib. Dual Myeloid Disorder Treated with Two Drug Association

  Katia Paciaroni, Selenia Campagna, Nicoletta Villiva', Enrico Maffini, Francesca Celesti, Attilio Tordi, Mariangela Lombardi, Giulia Dragonetti, Tommaso Caravita di Toritto

  e2025023

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.023

  1025

  PDF: 1025

  HTML: 89

• DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA

  Sabina Chiaretti, Gina Zini, Renato Bassan

  e2014073

  2014-10-24

  https://doi.org/10.4084/mjhid.2014.073

  8955

  PDF: 6007

  HTML: 87920

  Fig.1b: 172

  Fig.1c: 171

  Fig.2a: 164

  Fig.2b: 163

  Fig.4: 175

  Fig.2c: 170

  Fig.3: 169

  Tab.1: 215

  Tab.2: 194

  Tab.3: 180

  Tab.4: 207

  Fig1a: 165

• EBV-RELATED LYMPHOPROLIFERATIVE DISEASES: A REVIEW IN LIGHT OF NEW CLASSIFICATIONS EBV-RELATED LYMPHOPROLIFERATIVE DISEASES

  Pietro Tralongo, Arianna Bakacs, Luigi Maria Larocca

  e2024042

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.042

  4040

  PDF: 1556

  HTML: 886

• Ph-negative chronic myeloproliferative neoplasm (primary myelofibrosis)– as one of the reasons of the Budd-Chiari syndrome.

  Maria Dmitrievna Sanatko

  e2012047

  2012-06-30

  https://doi.org/10.4084/mjhid.2012.047

  2295

  PDF: 832

  HTML: 660

  Untitled: 142

• HYDROXYCARBAMINE: FROM AN OLD DRUG USED IN MALIGNANT HEMOPATHIES TO A CURRENT STANDARD IN SICKLE CELL DISEASE

  Giovanna Cannas, Solene Poutrel, Xavier Thomas

  e2017015

  2017-02-15

  https://doi.org/10.4084/mjhid.2017.015

  3869

  PDF: 1142

  HTML: 1640

• CHRONIC MYELOPROLIFERATIVE NEOPLASMS: A COLLABORATIVE APPROACH

  Lisa Pieri, Paola Guglielmelli, Alessandro Maria Vannucchi

  e2010017

  2010-06-18

  https://doi.org/10.4084/mjhid.2010.017

  1640

  PDF: 709

  HTML: 2329

• NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL

  Dimitar Efremov, Adrian Wiestner, Luca Laurenti

  e2012067

  2012-10-09

  https://doi.org/10.4084/mjhid.2012.067

  2457

  PDF: 828

  HTML: 8800

  Efremov 1: 209

  Efremov 2: 171